NCT01627665 - Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Healthy Volunteers

Interventions

DRUG

D->R->C+R

one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg

DRUG

D->R->C+D

one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg

DRUG

R->D->C+D

RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg

DRUG

R->D->C+R

RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg

Trial Locations (1)

CIC Hopital europeen george pompidou, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER